How to take Lurbinectedin

How to take Lurbinectedin

1. Common dosage for adult small cell lung cancer

Intravenous infusion of 3.2 mg/m² every 21 days, over 60 minutes.

2. Treatment duration

Until disease progression or unacceptable toxicity occurs.

3. Note

Use only when the absolute neutrophil count (ANC) is at least 1500 cells/mm³ and the platelet count is at least 100,000/mm³.

4. Consider using antiemetic prophylaxis before infusion

Corticosteroids (dexamethasone 8 mg intravenously or equivalent).

Serotonin antagonist (ondansetron 8 mg intravenously or equivalent).

5. Dosing recommendations

Rupitidine is only for intravenous injection.

Check for particulate matter and discoloration before administration. Do not administer if observed.

Rupitidine can be administered with or without an in-line filter. If an in-line filter is used, a polyethersulfone in-line filter with a pore size of 0.22 micron is recommended.

Consider the use of a central venous catheter, especially in patients with limited venous access, to reduce the risk of extravasation.

The pictures are from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Lurbinectedin dose adjustment

1. Renal function dose adjustment

No data available.

2. Liver function adjustment dose

(1), mild hepatic insufficiency (total bilirubin [TB] ≤ upper limit of normal [ULN] and AST>ULN, or TB between 1 and 1.5 times ULN and any AST): Dosage adjustment is not recommended.

(2), Moderate to severe hepatic insufficiency (TB>1.5 times ULN and any AST): No data available.

3. Dose adjustment for patients who develop hepatotoxicity during treatment

(1), Level 2: Suspend treatment until recovery to level 1 or below; resume treatment at the same dose.

(2), Grade 3 or above: Suspend treatment until recovery to Grade 1 or below; resume treatment at a reduced dose or permanently discontinue treatment.

4. Recommended dose reduction for adverse reactions

(1), first dose reduction: intravenous infusion of 2.6 mg/m² every 21 days, infusion time over 60 minutes

(2), second dose Dose reduction: intravenous infusion of 2 mg/m² every 21 days, infusion time over 60 minutes

Lurbinectedin storage requirements

Please follow appropriate special handling and disposal procedures.

If not used immediately after reconstitution or dilution, the solution can be stored in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature/ambient light for up to 24 hours before administration.

Store vials of rupitidine in the refrigerator at 2°C to 8°C (36°F to 46°F).

Warm Tips

1. Women of childbearing potential should contact their healthcare provider if they are pregnant or suspect they are pregnant.

2. Women of childbearing potential should take effective contraceptive measures during treatment and for at least 6 months after the last dose.

3. Men who have a female partner of childbearing potential should take effective contraceptive measures during treatment and for at least 4 months after the last dose.

4. Breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.